Lupin Limited

Lupin Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra, India. Founded in 1968, the company operates as a global pharmaceutical leader, primarily engaged in the development, manufacturing, and commercialization of a wide range of branded and generic formulations, active pharmaceutical ingredients (APIs), advanced drug delivery systems, and biotechnology products. Its core mission is to catalyze treatments that transform hope into healing, striving to provide affordable and quality healthcare to patients worldwide.

Lupin's diverse portfolio spans key therapeutic areas including paediatrics, cardiovascular, anti-infectives, diabetology, asthma, anti-tuberculosis, central nervous system, gastrointestinal, oncology, respiratory, women's health, and ophthalmology. Key products include generic versions of Tiotropium Bromide Inhalation Powder (generic Spiriva®), Empagliflozin and Linagliptin tablets, Huminsulin, and recently launched Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the US. The company's offerings also encompass specialty medicines like Xopenex HFA®, NaMuscla, and Cuprimine. Lupin maintains a significant global footprint, distributing its products in over 100 markets, with a strong presence in the United States, India, Japan, Europe, and Australia.

Lupin is a publicly traded entity, listed on the BSE (500257) and NSE (LUPIN). As of FY25, it holds the position of the 3rd largest generic pharmaceutical company in the U.S. by prescriptions and ranks among the top pharmaceutical companies in the Indian market. The company is led by CEO Vinita D. Gupta and Managing Director Nilesh Gupta, with Manju D. Gupta serving as the Non-Executive Chairperson. Recent activities include the April 2026 launch of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the US, the completion of the acquisition of VISUfarma B.V., and a $30 million settlement in antitrust litigation with Humana Inc.